Phase I Study on Safety, Tolerability, and Pharmacokinetics of IMP21052 in Healthy Volunteers

The primary objective of this clinical study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of the investigational medicinal product IMP21052 when administered intravenously in a single-dose escalation manner. This study is conducted in a randomized, double-blind, placebo-controlled setting involving healthy male and female volunteers. The clinical relevance of this objective lies in determining the initial safety profile and pharmacokinetic parameters of IMP21052, which is crucial for its potential development as an **antidote**. No secondary objectives are specified for this study.

The clinical trial involves a study population comprising both **male** and **female** participants. The age range of the participants is categorized under code "3," which typically includes adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. The study is related to an **antidote**, although specific details about the medical condition or the main objective of the trial are not disclosed. The selection criteria for the trial population, including any lifestyle considerations such as diet or physical activity, have not been specified by the sponsor. Key inclusion or exclusion criteria are also not provided.

This clinical trial is a **phase I**, single-center, randomized, double-blind, single-dose escalation, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of IMP21052 administered intravenously. The trial involves healthy male and female volunteers and is focused on assessing the investigational product as an **antidote**. The study is structured to ensure rigorous scientific evaluation through its randomized and double-blind design, minimizing bias and ensuring reliable results.

The trial is expected to commence recruitment on November 27, 2023, and is estimated to conclude by September 1, 2024. Participants will be involved in the study for a duration that aligns with the trial's timeline, with specific involvement periods determined by the dosing schedule and follow-up requirements. The sequence of study visits includes an initial screening visit to assess eligibility, followed by dosing visits where the investigational product or placebo is administered. Subsequent follow-up visits are scheduled to monitor safety and collect pharmacokinetic data. The end-of-study visit marks the completion of the participant's involvement, where final assessments are conducted to ensure participant safety and gather concluding data.

Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, if they withdraw consent, or if they fail to comply with the study protocol. The trial's design and procedures are meticulously planned to uphold the highest standards of clinical research, ensuring the collection of robust and reliable data while prioritizing participant safety and well-being.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be provided. The trial documentation does not include any additional relevant information about drug administration or participant compliance monitoring.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of November 27, 2023, and an estimated end date of September 1, 2024. The efficacy assessment will be conducted at predetermined intervals throughout the trial duration. Specific parameters or endpoints for evaluating efficacy have not been detailed in the available data. The trial will adhere to standard protocols for data collection and analysis, ensuring that all efficacy assessments are conducted systematically and consistently. The use of validated tools and instruments for measuring efficacy will be implemented as per the trial's protocol, although specific tools are not mentioned in the provided information. The trial's design will ensure that all efficacy-related data is collected and analyzed in a manner that aligns with the scientific and regulatory standards expected in clinical research.